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Abstract 
In our study it was aimed to research the relations between pregnancy complications and frequencies 
of maternal and fetal complications which can be observed after the further follow-ups with 
biochemical indicators in gravid individuals whom found to be risky in quad test.120 patients who 
applied and had their labors conducted in İstanbul Training and Research Hospital and took quad 
test AFP (alpha fetoprotein), HCG (human chorionic gonadotropin), uE3 (unconjugated estriol), 
inhibin-A are included in our study. Conclusions planned to be obtained in this study are, IUGR 
(intrauterine growth deficiency), macrosomia, gestational diabetes, preeclampsia and preterm birth. 
64 (% 53, 4) out of 120 patients participated in the study had normal labors while 56 (%46, 6) of the 
patients had labors with caesarean birth. On 70 (%58.3) patients whom did not develop obstetric 
complications, AFP value calculated as average as 1.00±0.74 MoM, uE3 value calculated as  
0.89±0.4 MoM, hCg value calculated as 0.97±0.5 MoM and inhibin A value calculated as an average 
of  0.95±0.5 MoM.  On 50 (%41.6) patients whom developed obstetric complications, AFP value 
found as average of 1,06±0,74, uE3 value found as 0.96±0.39 MoM, hCG value found as 0.99±0.77 
MoM and Inhibin A value found as 1.023±0.62 MoM. There were no significant deviation between 
the cases with obstetric complications and cases without obstetric complications in terms of AFP, 
uE3, HCG and Inhibin A values. There were no significant relation between threshold values of 
AFP, HCG, uE3 and inhibin A which are used in quad test as secondary trimester serum indicators 
in low risk populations and pregnancy complications. 
 
Keywords: Serum scan test; alfa-fetoprotein; human chorionic gonadotropin; inhibin A; bad obstetric 
results. 
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Introduction 
During antenatal follow up, using biochemical screen tests besides ultrasonography for 
diagnosing fetal anomalies provided better pregnancy results.  Besides assignation of risk for 
chromosomal and structural anomalies, biochemical indicators used in screen tests found to be 
used for forecasting pregnancy complications (Bobyr & Vile, 2005; 152). In the early 1970s the 
only method for diagnosing Down syndrome in fetus was the age of the mother; all the women 
at the age of 35 or above were suggested to conduct amniocenteses.  During 1980s secondary 
trimester mother serum biochemical indicators added to the age of the mother as a new screening 
method (James et al., 2008).  At the start of the usage of triple test Down syndrome diagnosis 
rate obtained as %70. the 16th week of the pregnancy median values of AFP (alpha fetoprotein), 
uE3 (unconjugated estriol), hCG( human chorionic gonadotropin) concentrations found to be 
different in the gravids carrying trisomy 21 fetus compared to normal fetus carrying mothers.   
Screen test called as "triple test" was suggested for by considering that these hormones might be 
used for screening the risky groups.  Different indicators combined in order to increase the 
sensibility of the biochemical screen test. Addition of Inhibin-A to triple screen test is the most 
commonly used one. On the pregnancy with Down syndrome it was reported that though inhibit. 
An increases it cannot be used for calculating the trisomy 18 risk (Kafkaslı, 2004).  On the  
gravids diagnosed with lower levels of PAPP-A (Pregnancy-Associated Plasma 
Protein),complications as intrauterine growth deficiency (IUGR), premature birth, preeclampsia 
and stillbirth are observed to be increasing compared to  gravids which are not diagnosed with 
lower levels of PAPP-A (Smith et. al., 2002). On the gravids diagnosed with higher β-hCG levels, 
IUGR, preterm birth, preeclampsia and fetal loss rates observed to be increasing compared to 
gravids with normal β-hCG levels (Chandra et. al., 2003).  Thus there are some studies reporting 
the relation between lower estriol levels and further preeclampsia, it is not a sensitive indicator 
(Lindheimer et. al., 2003). Human placenta, decidua and fetal membranes are the major areas for 
production of mother serum, amniotic fluid, inhibin-A and inhibin-B in cord blood. Inhibin-A 
found in mother's blood mainly synthesized by placenta (Wallace et. al., 1997). Neural tube 
deficiency (NTD) is the secondary commonly observed fetal congenital malformation following 
cardia anomalies (Knoshnood et. al., 2011). Alpha fetoprotein is used in NTD screening for over 
30 years while ultrasonography (USG) is used for diagnosis. (Krantz et. al., 2010). As skin to be 
intact on %10 of the NTDs, while higher MSAFP values are not found in these cases, it is not 
efficient for NTD screening (Cameron & Moran, 2009). 
 
Material and Methods 
In our study it was aimed to study the relations between complications of pregnancies 
and frequencies of maternal and fetal complications which can be observed after the further 
follow-ups with biochemical indicators in gravids whom found to be risky in quad test for Down 
syndrome. 
120 patients which are applied to pregnancy policlinic  of Istanbul Training and Research 
Hospital between 2 January 2012 and 2 July 2013 and conducted quad test (AFP, hCG, uE3) 
(AFP: Alfa-Fetoprotein,  hCG: Human Chorionic Gonadotropin, uE3:unconjugated oestriol), 
inhibin-A ) and had  their labors in our hospital were included in the study. Quad test results and 
obstetric complications of the patients participated in the study were compared. Study conducted 
in İstanbul Training and Research Hospital perinatology and delivery unit following the approval 
from Hospital Training and Planning Committee and Committee of Ethics.    Within the 
indicated dates, patients considered within the scope of the study were informed and included in 
the study following their signed approval on the form of approval. 
Criterias for inclusion in our study, are singleton gravids who took quad test between 
16th and 20th week as per their last menstruation date, no presence of miscarriage risk (vaginal 
bleeding, pain etc.), no exposure to medication or radiation during the pregnancy within study 
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period, no consanguineous marriage, no presence of blood incompatibility, no history of baby 
birth with fetal anomaly and be aged between 16 and 42.  Exclusion criterias in our study are 
multiple pregnancy, no observation of fetal hearth beat between 16th and 20th weeks, fetal 
anomaly diagnosed in ultrasound, gravids who did not conduct labor in our hospital, individuals 
diagnosed with diabetes in presentational period, presence of bad obstetric history and  gravids 
below 16 years of age and older than 42 years of age. In addition to the quad test markers of the 
120 gravids within in the criterias of the study; obstetric histories, physical examinations, fetal 
obstetric ultrasonography, amniotic fluid indexes, birth types, Aantenatal and postnatal pregnancy 
complications (preeclampsia, early membrane rupture, preterm birth, Small Gestational Age 
(SGA), gestational diabetes Mellitus (GDM)) biochemical results were searched from the patients' 
files. Labor types and fetal birth weight information were collected from birth registrations by 
retrospective inspections. Information of the patients were evaluated after the labor.  
Findings planned to be obtained as a result of this study comprised of intrauterine growth 
deficiency (IUGR), macrosomia, gestational Diabetes (GDM), preeclampsia and preterm birth.  
Babies born below the 10th percentile as per the pregnancy week are accepted as small 
gestational age (SGA).  Macrosomia as per the pregnancy age was used for defining the newborns 
which were born over 90th percentile of gestation week in terms of birth weight. Heavy 
preeclampsia, if no  preeclampsia proteinuria were present, defined as the presence of symptoms 
and/or findings or 1+ or more proteinuria and blood pressure over 140/90mmHg. Birth before 
the 37th pregnancy week defined as preterm birth. 2 of the 100 gram oral glucose tolerance test 
results to be higher as per ACOG criteria accepted as gestational diabetes.  PPROM (Preterm 
premature rapture of membranes) described as the arrival of amnion fluid as a result of the 
spontaneous tearing of amnion membrane before 1 or more hours prior to start of the activity 
before 37th pregnancy week. 
 
Statistical Analysis 
Descriptive and analytical statistical analysis were conducted for all the patients using 
SPSS 15.0 (Statistical Package for the Social Sciences Inc.; Chicago, IL, ABD) software. For 
continuous measured variables, descriptive statistics were presented as average ± and standard 
deviation as presenting minimum and maximum values while quantitative variables were 
presented as number of cases and percentiles (%). Presence of statistically  significant deviation 
between groups in terms of normal distributed continuously measured variables  were evaluated 
with T test while the importance of the deviance between the groups for non-normal distributed 
continuously measured variables were evaluated with  Mann Whitney U test. Study groups 
evaluated in two groups as gravids with complications and gravids without complications during 
these analysis. In order to determine the more efficient factor in preeclampsia, preterm birth and 
IUGG, logistic regression analysis conducted. p< 0.05 accepted as statistically significant. 
 
Results 
Relations between pregnancy complications and secondary trimester screening results 
with HCG, AFP, uE3 and Inhibin a MoM values for 120 cases were evaluated. While IUGR were 
included in macrosomia, preterm birth, preeclampsia, gestational diabetes and gravids developed 
fetal distress complication group, gravids without problems in antenatal follow-up are comprised 
the group of patients without complications. 50 (41.6%) of the patients experienced problems in 
antenatal follow-ups while 70 (58.3%) of the patients did not develop complications.  As we look 
on the demographical specifications of the cases included in the study, average age in the group 
without complications found as 29.46 ± 5.87 and average age in the complication group found as 
27.74 ± 5.92.  Average weight of the non-complications found as 65.52 ± 10.32 kg and body 
mass index (BMI) were found as 25.08 ± 4.14 kg/m2 and average weight for the complications 
group found as 64.26 ± 8.95 kg and BMI was found as 24.76 ± 3.97 kg/m2. Age of the mother, 
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weight, height and BMI values for the complication group and non-complication groups are 
given in Table 1. There is no significant deviance between the cases in terms of age of mother, 
weight, height and BMI (p>0.05). 
 
Table 1. Age of Mother, weight, height and BMI values for the complication group and 
non-complication groups. 
 Complication Unpresented Complication Present p 
M sd M sd 
Age (years) 29.46 5.87 27.74 5.92 ,115 
Weight 65.52 10.32 64.26 8.95 ,488 
Height 161.85 6.10 161.40 6.52 ,701 
BMI 25.08 4.14 24.76 3.97 ,680 
 BMI: Body Mass Index, M: Mean, SD: standard deviation 
 
64 (53.4%) out of 120 patients participated in the study had normal childbirths while 56 
(46.6%) of the patients had childbirths with caesarean birth. As the genders of the newborns 
considered for the 120 cases participated in the study, 59 (49.1%) male babies and 61 (50.8%) 
female babies were given birth.  Distribution of the birth type and gender are given in table for 
complication and non-complication groups in Table 2. There is no significant deviation between 
the complication and non-complication group in terms of birth type and gender distribution 
(p>0.05). 
 
Table 2. Distribution of birth type and gender between complication and non-
complication group. 
 Complication Unpresented Complication Present p 
n % n % 
Birth Type      
NSD 40 57.1 24 48.0  
Caesarean 30 42.9 26 52.0 0.332 
Sex      
Male 34 48.6 25 50.0  
Female 36 51.4 25 50.0 0.877 
    NSD: Normal Spontaneous Birth 
 
2 of the cases were observed with preeclampsia (4%), 5 were observed with IUGR (10%), 
1 observed with early membrane rapture (EMR) (2%), 20 observed with preterm activity (40%), 7 
observed with fetal distress, 6 observed with GDM (12%) and 9 observed with macrosomia 
(18%) out of 120 gravids participated in the study (Table 3). 
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Table 3. Pregnancy Complication and Frequency 
Complication n % 
IUGR 5 10.0 
Preeclampsia 2 4.0 
EMR 1 2.0 
Fetal Distress 7 14.0 
GDM 6 12.0 
Preterm Activity 20 40.0 
Macrosomia 9 18.0 
Total 50 100.0 
IUGR: Intrauterine Growth Deficiency EMR: Early Membrane Rupture GDM: Gestational 
Diabetes Mellitus 
 
Figure 1. ROC curve  
 
Area below the curve 
AFP: Alfa-Fetoprotein HCG: Human Chorionic Gonadotropin, uE3: Unconjugated oestriol, 
ROC: Receiver Operating Characteric 
 
Table 4. Relation between AFP, uE3, HCG and inhibin-A values and complication 
development in ROC analysis   
 Area Std. Error Asp. Sig. Asymptomatic 95%   confidence 
interval 
     Lower Limit Upper Limit  
 AFP .476 .054 .650 .370 .581 
 uE3 .559 .053 .275 .454 .663 
 hCG .493 .054 .894 .386 ,599 
 Inhibin A .521 .053 .699 .416 .625 
AFP: Alfa-Fetoprotein,   HCG: Human Chorionic Gonadotropin, uE3: Unconjugated oestriol 
 
 
Dinc, K., Ozyurt, R., Sık, A., Kumbasar, S., Akpak, Y. K., & Aba, Y. A. (2017). Effects of secondary trimester maternal 
serum screening on the results of pregnancy. Journal of Human Sciences, 14(4), 3653-3662. 
doi:10.14687/jhs.v14i4.4806  
 
 
3658 
No significant deviation between AFP, uE3, HCG and inhibin-A values and complication 
development found within the conducted ROC analysis. As AFP MoM threshold values 
considered as 1.5, 2.0 and 2.5, relation between complication observation frequency and AFP 
MoM values over threshold values found to be insignificant. (p=0.268 p=0.224 p=0.229 
respectively). As HCG MOM threshold values considered as 1.5 and 2.0, relation between 
complication observation frequency and HCG MOM values over these threshold values found to 
insignificant. (p=0.479, p=0.872). As threshold value for uE3 MoM considered as 0.8 relation 
between complication observation frequency and uE3 MoM values over these threshold values 
found to significant. (p=0.001). In other words, as the threshold values of uE3 MoM values 
considered as 0.6, 0.7, 0.8 and 0.9 a significant relation between complication observation 
frequency and uE3 MoM values over these threshold values were identified (p=0.129). 
As threshold values of Inhibin-A MoM considered as 1.5 and 2.0, relation between 
complication observation frequency and HCG MoM values over these threshold values found to 
be insignificant (p=0.87, p=0.910 respectively). 
Out of 120 cases participated in the study for 70(%58.3) non-complication cases average 
AFP value calculated as 1,00 ± 0,74 MoM,uE3 value calculated as 0,89 ± 0,4 MoM, hCG value 
calculated as 0,97 ± 0,5 MoM and average Inhibin A value calculated as 0,95 ± 0,5 MoM.  For 50 
(%41.6) cases developed complications, average AFP value calculated as 1,06 ± 0,74, uE3 value 
calculated as 0,96 ± 0,39 MoM, hCG value calculated as 0,99 ± 0,77 MoM and Inhibin-A value 
calculated as 1,023 ± 0,62 MoM. There is no significant deviation between complication and 
non-complication group in terms of AFP, uE3, HCG and Inhibin-A values (p>0, 05) (Table 5). 
 
Table 5. Comparison of complication and non-complication groups in terms of AFP, uE3, HCG 
and Inhibin A values 
   Complication Unpresented  
(n=70) 
Complication Present (n=50) p 
M sd M sd 
AFP 1.0080 ,7440 1,069 ,7427 ,615 
uE3 .8955 ,4089 ,9668 ,3900 ,274 
hCG .9734 ,5482 ,9942 ,7717 ,850 
Inhibin A .9568 ,5281 1,0235 ,6251 ,699 
AFP: Alfa-Fetoprotein, HCG: Human Chorionic Gonadotropin, uE3: Unconjugated oestriol M: 
Mean 
 
Discussion 
Purpose of the screening tests is to screen biggest population possible and diagnose the 
high risk pregnancies in terms of genetic diseases. For this purpose, ultrasonography and analysis 
methods of biochemical indicators in maternal blood are commonly used in present times.  Thus 
there is no agreement over the prenatal screen tests, a lot of studies still conducted on this subject 
(Brock et al., 1999; Hamilton et. al. 1985). Conducted studies focused either on developing a new 
protocol or specificity and sensitivity in birth anomalies (Brock et al., 1999; Hamilton et. al. 
1985). Threshold values of secondary trimester MSAFP, HCG, uE3 and Inhibin-A are reported 
in different studies. 
First Brock et. al (1997) researched the presence of relation between maternal AFP level 
and low birth weight and reported 2.5 times more low birth weight for the cases where the AFP 
values are over 2.3 threshold value. Hamilton et. al. (1985) who considered AFP threshold value 
as 2.5 Mom, reported 10 times lower birth rate, 10 times more preterm activity risk, 3 times more 
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ablatio placenta risk and 8 times more perinatal death risk for the cases with AFP levels over this 
threshold value.  In our study AFP values are observed as <= 1.5 MoM for 47(94.0%) for 
pregnancies with complication against 3 (6.0%) pregnancies without complication with AFP 
values as > 1.5 MoM. If we consider AFP threshold values as 2 and 2.5 MoM, we observed <49 
(98.0%) and 1 (2%) complicated pregnancies for the both two truncations. No statistically 
significant risk increase found. In our study, this kind of a risk increase were not identified 
however the reason behind this might be because of our study with low risk population. No 
significant increase in the risk observed in our study between normal and low birth weight for the 
whole AFP MoM threshold values in our study (1.5, 2.0 and 2.5). In most of the studies, 2 or 2.5 
MoM levels used as truncation values for describing the higher AFP status. We did not find any 
high risk relation between AFP values and pregnancy complications as IUGR, Preterm Activity-
Birth, GDM, EMR, and preeclampsia. 
Relation between secondary trimester maternal serum HCG level and pregnancy 
complications drew attention of the many researchers. Abnormal increase in HCG levels might 
result in decrease of the placental perfusion by decreasing the oxygenation of cytotrophoblast. 
Lieppman et. al. (1993) used 2 MoM as the threshold value and reported 2, 8 times increased rate 
of premature birth risk, 4 times increased low birth weight risk for the gravids over this threshold 
value. In our study, we identified 37 (84.0%) complicated pregnancies with HCG threshold value 
of ≤ 1.5 MoM against 13 (16.0%) complicated pregnancies with HCG value of > 1.5 MoM. By 
considering HCG threshold value as <2 Mom, we identified 46 (92.0%) complicated pregnancies 
and identified 4 (8.0%) complicated pregnancies as we considered threshold value as > 2 MoM. 
No statistically significant risk increase found.  This kind of risk were not identified in our study. 
In most of the studies, 2 or 2.5 MoM levels used as truncation values for describing the higher 
HCG status. We did not find any high risk related between HCG values and pregnancy 
complications as IUGR, Preterm Activity-Birth, GDM, EMR, and preeclampsia. 
Two mechanisms asserted regarding higher HCG levels. First theory is "reactive 
hyperplasia of the cytotrophoblastic cells exposed to hypoxia". According to an another 
hypothesis, weight and volume of the placenta is greater in the cases where the HCG levels 
increased, and as a result it might be reflecting a healthier placental implantation with bigger 
babies (Sayın et. al., 2008). However, Mikic & Johnson (1999), claimed that higher isolated 
maternal serum beta-hCG levels are not an indicator for other pregnancy complications and 
IUGG. 
We did not find any statistically significant relationship between serum HCG levels and 
pregnancy results as similar to Mikic & Johnson (1999). In our study, we identified 37 (84. 0%) 
complicated pregnancies with HCG threshold value of ≤ 1.5 MoM against 13 (16.0%) 
complicated pregnancies with HCG value of > 1.5 MoM. By considering HCG threshold value 
as <2 MoM, we identified 46 (92.0%) complicated pregnancies and identified 4 (8.0%) 
complicated pregnancies as we considered threshold value as > 2 MoM.  No statistically 
significant risk increase found. No comparison between these groups conducted as a result of 
having low number of patients with AFP and HCG values of 2.5 MOM.  Our study needs to be 
supported by increasing the number of patients and conducting prospective studies.   
Smith et. al. (2007).  compared the PAPP-A and β-hCG values with pregnancy results in 
8839 gravids which were in their 8th and 14th weeks, and stated that gravids with PAPP-A values 
lower than 5 % are exposed to IUGR, premature birth, preeclampsia and stillbirth risks while for 
the gravids with free  β-hCG values below 5 percentile are exposed to IUGR risk. Huang et. al. 
(2010) in their retrospective compositions including 141698 gravids, relation between 
biochemical indicators obtained during first and secondary trimester and Down Syndrome 
screening and pregnancy results and as compared with the control group AFP and total hCG 
levels found to be significantly higher in terms of preeclampsia, IUGR and fetal loss while PAPP-
A and oestriol levels found to be significantly lower. In an another retrospective cohort study 
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conducted with 2844 cases multiple of Median (MoM) value for β-hCG and PAPP-A found to be 
lower compared to control group in terms of preeclampsia, premature birth, IUGR and 
decollement placenta cases (Ranta et. al., 2011). In some studies for the PAPP-A MoM value 
inspected between 11th and 13th pregnancy week, thus reported to be lower compared to control 
cases in terms of preeclampsia (Carbone et. al., 2011; Poon et. al., 2010), in some cases no 
differences between the groups were found (Mikat et. al., 2012; Vandenberghe et. al., 2011), and 
screening performance of serum PAPP-A for early start preeclampsia and IUGR reported as 
week (Vandenberghe et. al., 2011). 
In addition to AFP and hCG results, there are limited number of studies conducted on 
researching the relation between uE3 levels and pregnancy complications.  Pergament et. al. 
(1995) considered the threshold value as 0.75 for trimester screening and pregnancy complication 
values and found the occurrence of intrauterine growth deficiency to be more frequent for the 
gravids whom have MoM levels below the threshold value. Kowalczyk et. al. (1998) reported that 
the occurrence of intrauterine growth deficiency and oligohydramniosis to be significantly more 
frequent for the gravids with uE3 levels below 0.75 MoM threshold value. Ben et. al. (1996), 
reported that more number of bad pregnancy results observed in the cases with higher secondary 
trimester AFP and HCG levels. In a similar study like ours which were conducted in Turkey, no 
relation between lower indirect oestriol levels with preterm activity, IUGR, macrosomia, fetal 
distress found only, but a relation with GDM were found for uE3≤ 0.5 MoM.  In our study, we 
identified 3 (6.0%) complicated pregnancies with uE3  threshold value of ≤0.6 MoM against  47 
(94.0%) complicated pregnancies with hCG value of  > 0.6 MoM. We did not identified a 
statistically significant increase in preterm activity, IUGR, macrosomia and EMR. 
Inhibin-A is known as the only roaming mature inhibin type during pregnancy. In the 
published articles Tul et. al. (2003) reported a significant relationship between higher Inhibin-a 
levels and preterm birth. Diagnosis of preeclampsia were left for the weeks between 20 and 22 as 
the preeclampsia symptoms usually develop during late secondary trimester and 3rd trimester. , 
In an another study, a relation between the high levels of Inhibin-A in mother's serum in 
secondary trimester and preeclampsia and IUGR (D'Anna et. al., 2002).  Lambert-Messerlian et al 
(2000) stated that, for the cases in secondary trimester with higher Inhibin-A and hCG levels 
developed a high rate of late start preeclampsia while stating Inhibin-A's superiority for 
identifying early start preeclampsia.  In our study we identified 44 (89.2%) complicated cases with 
Inhibin-A MoM values <2 and 6 (10.2%) cases with Inhibin-A MoM values with > 6 while  there 
is not a significant relationship if threshold value for Inhibin-A MoM considered as 2.0. 
(p=0.910). In our study, we did not find high risk related with inhibin a for the pregnancy 
complications as IUGR, preterm activity-birth, GDM, EMR and preeclampsia.  
Spencer et al. (2006) conducted a case control study comprised of 24 cases with 
developed preeclampsia and 144 normotensive cases. PAPP-A, free β-HCG activine A, inhibin A 
levels were inspected in the cases between 22nd and 25th pregnancy weeks, a significant increase 
found for group which developed  preeclampsia compared to control group in terms of serum 
PAPP-A, free β-hCG, activine A and activine B levels.  Lower levels of PAPP-A (<0.4 MoM) 
and  hCG (<0.5 MoM) levels in first trimester, higher levels of AFP (>2.5 MoM), HCG (>3 
MoM), inhibin A (≥ 2 MoM)  and lower levels of AFP (<0.25 MoM), E3 (< 0.5 MoM) in 
secondary trimester are reported to be in relation with increased pregnancy complications, but at 
the same time it was reported that these indicators have lower sensitivity for identifying obstetric 
complications and having high rate of false positive identifications; and if high levels of AFP is 
present in secondary or third trimester with placenta praevia,  placenta acreata, increata, percreata  
should be suspected (Gagnon et. al., 2008).  
Dugoff et. al. (2005) for the 33145 cases where AFP, hCG, E3 and Inhibin A inspected; 
reported increased pregnancy complications where one of the values are abnormal while reported 
increased pregnancy complications with increased significance in the presence of more than one 
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abnormal parameters. However, the sensitivity of these parameters for identifying the pregnancy 
complications is low.  
 
Conclusion 
No significant relation between threshold values of AFP, hCG, uE3 and inhibin A which 
are used in quad test as secondary trimester serum indicators in low risk populations and 
pregnancy complications. In order the decrease bad fetomaternal results, more prospective 
studies including bigger populations with greater number of patients required to be conducted 
regarding increasing the fetal survival. 
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